Antitumor activity of FL118, a survivin, Mcl-1, XIAP, and cIAP2 selective inhibitor, is highly dependent on its primary structure and steric configuration

Molecular Pharmaceutics

Volumn 11, Issue 2, 2014, Pages 457-467

  Zhao, Jiuyang ^a   Ling, Xiang ^b   Cao, Shousong ^c   Liu, Xiaojun ^b   Wan, Shengbiao ^a   Jiang, Tao ^a   Li, Fengzhi ^b,d  

^a OCEAN UNIVERSITY OF CHINA   (China)

^b Departments of Pharmacology and Therapeutics   (United States)

^c Medicine and   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

camptothecin analogue; cancer cells; FL118; human tumor animal models; IAP inhibitor; SAR analysis

Indexed keywords

10,11 METHYLENEDIOXYCAMPTOTHECIN 20 O(3 BROMOBENZOATE); 10,11 METHYLENEDIOXYCAMPTOTHECIN 20 O(3 IODOBENZOATE); 10,11 METHYLENEDIOXYCAMPTOTHECIN 20 O(3,4 DIMETHOXYBENZOATE); 10,11 METHYLENEDIOXYCAMPTOTHECIN 20 O(4 CHLOROBENZOATE); 10,11 METHYLENEDIOXYCAMPTOTHECIN 20 O(4 IODOBENZOATE); 10,11 METHYLENEDIOXYCAMPTOTHECIN 20 O(4 NITROBENZOATE); 10,11 METHYLENEDIOXYCAMPTOTHECIN 20 O(4BROMOBENZOATE); ANTINEOPLASTIC AGENT; CELL DNA; FL 118; HYDROXYL GROUP; INHIBITOR OF APOPTOSIS PROTEIN 2; IPRIFLAVONE; IRINOTECAN; LACTONE; PROTEIN MCL 1; SURVIVIN; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS; 1,3 BENZODIOXOLE DERIVATIVE; 7-ETHYL-7-HYDROXY-10H-1,3-DIOXOLO(4,5-G)PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLINE-8,11(7H,12H)-DIONE; INDOLIZINE DERIVATIVE; INHIBITOR OF APOPTOSIS PROTEIN; MICROTUBULE ASSOCIATED PROTEIN; PROTEIN BINDING;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL DESTRUCTION; CANCER INHIBITION; CANCER SIZE; CELL DEATH; COLON CANCER; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG EFFICACY; DRUG SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; STRUCTURE ACTIVITY RELATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; SYNTHESIS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZODIOXOLES; CELL LINE, TUMOR; HUMANS; INDOLIZINES; INHIBITOR OF APOPTOSIS PROTEINS; MICROTUBULE-ASSOCIATED PROTEINS; MOLECULAR STRUCTURE; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84893267704     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp4004282     Document Type: Article

References (58)

1. Yoon, M. J.; Park, S. S.; Kang, Y. J.; Kim, I. Y.; Lee, J. A.; Lee, J. S.; Kim, E. G.; Lee, C. W.; Choi, K. S. Aurora B confers cancer cell resistance to TRAIL-induced apoptosis via phosphorylation of survivin Carcinogenesis 2012, 33, 492-500
2. Okamoto, K.; Okamoto, I.; Hatashita, E.; Kuwata, K.; Yamaguchi, H.; Kita, A.; Yamanaka, K.; Ono, M.; Nakagawa, K. Overcoming erlotinib resistance in EGFR mutation-positive non-small cell lung cancer cells by targeting survivin Mol. Cancer Ther. 2012, 11, 204-13
3. Park, E.; Gang, E. J.; Hsieh, Y. T.; Schaefer, P.; Chae, S.; Klemm, L.; Huantes, S.; Loh, M.; Conway, E. M.; Kang, E. S.; Hoe Koo, H.; Hofmann, W. K.; Heisterkamp, N.; Pelus, L.; Keerthivasan, G.; Crispino, J.; Kahn, M.; Muschen, M.; Kim, Y. M. Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia Blood 2011, 118, 2191-9
4. Trabulo, S.; Cardoso, A. M.; Santos-Ferreira, T.; Cardoso, A. L.; Simoes, S.; de Lima, M. C. P. Survivin Silencing as a Promising Strategy To Enhance the Sensitivity of Cancer Cells to Chemotherapeutic Agents Mol. Pharmaceutics 2011, 8, 1120-1131
5. Rahman, K. M. W.; Banerjee, S.; Ali, S.; Ahmad, A.; Wang, Z. W.; Kong, D. J.; Sakr, W. A. 3,3′-Diindolylmethane Enhances Taxotere-Induced Apoptosis in Hormone-Refractory Prostate Cancer Cells through Survivin Down-regulation Cancer Res. 2009, 69, 4468-4475
6. Li, F.; Ling, X. Survivin study: an update of "what is the next wave"? J. Cell. Physiol. 2006, 208, 476-86 (Pubitemid 44141872)
7. Rodel, F.; Hoffmann, J.; Distel, L.; Herrmann, M.; Noisternig, T.; Papadopoulos, T.; Sauer, R.; Rodel, C. Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer Cancer Res. 2005, 65, 4881-4887 (Pubitemid 40740827)
8. Carter, B. Z.; Mak, D. H.; Schober, W. D.; Cabreira-Hansen, M.; Beran, M.; McQueen, T.; Chen, W. J.; Andreeff, M. Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells Blood 2006, 107, 1555-1563 (Pubitemid 43242394)
9. Wu, J.; Ling, X.; Pan, D.; Apontes, P.; Song, L.; Liang, P.; Altieri, D. C.; Beerman, T.; Li, F. Molecular mechanism of inhibition of survivin transcription by the GC-rich sequence-selective DNA binding antitumor agent, hedamycin: evidence of survivin down-regulation associated with drug sensitivity J. Biol. Chem. 2005, 280, 9745-51 (Pubitemid 40409673)
10. Saito, T.; Hama, S.; Izumi, H.; Yamasaki, F.; Kajiwara, Y.; Matsuura, S.; Morishima, K.; Hidaka, T.; Shrestha, P.; Sugiyama, K.; Kurisu, K. Centrosome amplification induced by survivin suppression enhances both chromosome instability and radiosensitivity in glioma cells Br. J. Cancer 2008, 98, 345-55 (Pubitemid 351161250)
11. Zhang, M.; Latham, D. E.; Delaney, M. A.; Chakravarti, A. Survivin mediates resistance to antiandrogen therapy in prostate cancer Oncogene 2005, 24, 2474-82 (Pubitemid 40593038)
12. Roca, H.; Varsos, Z.; Pienta, K. J. CCL2 protects prostate cancer PC3 cells from autophagic death via phosphatidylinositol 3-kinase/AKT-dependent survivin up-regulation J. Biol. Chem. 2008, 283, 25057-73
13. Li, F. Compositions and Methods for Identifying Agents That Alter Expression of Survivin. WO Patent 2,008,073,201, 2008.
14. Ling, X.; Cao, S.; Cheng, Q.; Keefe, J. T.; Rustum, Y. M.; Li, F. A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity PloS One 2012, 7, e45571
15. Burke, T. G.; Mishra, A. K.; Wani, M. C.; Wall, M. E. Lipid bilayer partitioning and stability of camptothecin drugs Biochemistry 1993, 32, 5352-64 (Pubitemid 23167976)
16. Vogler, M.; Walczak, H.; Stadel, D.; Haas, T. L.; Genze, F.; Jovanovic, M.; Gschwend, J. E.; Simmet, T.; Debatin, K. M.; Fulda, S. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo Cancer Res. 2008, 68, 7956-65
17. Ding, X.; Mohd, A. B.; Huang, Z.; Baba, T.; Bernardini, M. Q.; Lyerly, H. K.; Berchuck, A.; Murphy, S. K.; Buermeyer, A. B.; Devi, G. R. MLH1 expression sensitises ovarian cancer cells to cell death mediated by XIAP inhibition Br. J. Cancer 2009, 101, 269-77
18. Connolly, K.; Mitter, R.; Muir, M.; Jodrell, D.; Guichard, S. Stable XIAP knockdown clones of HCT116 colon cancer cells are more sensitive to TRAIL, taxanes and irradiation in vitro Cancer Chemother. Pharmacol. 2009, 64, 307-16
19. Dai, Y.; Qiao, L.; Chan, K. W.; Zou, B.; Ma, J.; Lan, H. Y.; Gu, Q.; Li, Z.; Wang, Y.; Wong, B. L.; Wong, B. C. Loss of XIAP sensitizes rosiglitazone-induced growth inhibition of colon cancer in vivo Int. J. Cancer 2008, 122, 2858-63 (Pubitemid 351631390)
20. He, X.; Khurana, A.; Maguire, J. L.; Chien, J.; Shridhar, V. HtrA1 sensitizes ovarian cancer cells to cisplatin-induced cytotoxicity by targeting XIAP for degradation Int. J. Cancer 2012, 130, 1029-35
21. Ndozangue-Touriguine, O.; Sebbagh, M.; Merino, D.; Micheau, O.; Bertoglio, J.; Breard, J. A mitochondrial block and expression of XIAP lead to resistance to TRAIL-induced apoptosis during progression to metastasis of a colon carcinoma Oncogene 2008, 27, 6012-22
22. Zhao, X.; Laver, T.; Hong, S. W.; Twitty, G. B., Jr.; Devos, A.; Devos, M.; Benveniste, E. N.; Nozell, S. E. An NF-kappaB p65-cIAP2 link is necessary for mediating resistance to TNF-alpha induced cell death in gliomas J. Neurooncol. 2011, 102, 367-81
23. Miura, K.; Karasawa, H.; Sasaki, I. cIAP2 as a therapeutic target in colorectal cancer and other malignancies Expert Opin. Ther. Targets 2009, 13, 1333-45
24. Shigemasa, K.; Katoh, O.; Shiroyama, Y.; Mihara, S.; Mukai, K.; Nagai, N.; Ohama, K. Increased MCL-1 expression is associated with poor prognosis in ovarian carcinomas Jpn. J. Cancer Res.: Gann 2002, 93, 542-50 (Pubitemid 34752911)
25. Takahashi, H.; Chen, M. C.; Pham, H.; Angst, E.; King, J. C.; Park, J.; Brovman, E. Y.; Ishiguro, H.; Harris, D. M.; Reber, H. A.; Hines, O. J.; Gukovskaya, A. S.; Go, V. L.; Eibl, G. Baicalein, a component of Scutellaria baicalensis, induces apoptosis by Mcl-1 down-regulation in human pancreatic cancer cells Biochim. Biophys. Acta 2011, 1813, 1465-74
26. Simonin, K.; Brotin, E.; Dufort, S.; Dutoit, S.; Goux, D.; N'Diaye, M.; Denoyelle, C.; Gauduchon, P.; Poulain, L. Mcl-1 is an important determinant of the apoptotic response to the BH3-mimetic molecule HA14-1 in cisplatin-resistant ovarian carcinoma cells Mol. Cancer Ther. 2009, 8, 3162-70
27. Mitchell, C.; Yacoub, A.; Hossein, H.; Martin, A. P.; Bareford, M. D.; Eulitt, P.; Yang, C.; Nephew, K. P.; Dent, P. Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo Cancer Biol. Ther. 2010, 10, 903-17
28. Guoan, X.; Hanning, W.; Kaiyun, C.; Hao, L. Adenovirus-mediated siRNA targeting Mcl-1 gene increases radiosensitivity of pancreatic carcinoma cells in vitro and in vivo Surgery 2010, 147, 553-61
29. Wei, S. H.; Dong, K.; Lin, F.; Wang, X.; Li, B.; Shen, J. J.; Zhang, Q.; Wang, R.; Zhang, H. Z. Inducing apoptosis and enhancing chemosensitivity to gemcitabine via RNA interference targeting Mcl-1 gene in pancreatic carcinoma cell Cancer Chemother. Pharmacol. 2008, 62, 1055-64
30. Martin, A. P.; Miller, A.; Emad, L.; Rahmani, M.; Walker, T.; Mitchell, C.; Hagan, M. P.; Park, M. A.; Yacoub, A.; Fisher, P. B.; Grant, S.; Dent, P. Lapatinib resistance in HCT116 cells is mediated by elevated MCL-1 expression and decreased BAK activation and not by ERBB receptor kinase mutation Mol. Pharmacol. 2008, 74, 807-22
31. Lee, M.; Lapham, A.; Brimmell, M.; Wilkinson, H.; Packham, G. Inhibition of proteasomal degradation of Mcl-1 by cobalt chloride suppresses cobalt chloride-induced apoptosis in HCT116 colorectal cancer cells Apoptosis 2008, 13, 972-82
32. Ling, X.; Li, F. An intravenous (i.v.) route-compatible formulation of FL118, a survivin, Mcl-1, XIAP, and cIAP2 selective inhibitor, improves FL118 antitumor efficacy and therapeutic index (TI) Am. J. Transl. Res. 2013, 5, 139-54
33. Giovanella, B. C.; Hinz, H. R.; Kozielski, A. J.; Stehlin, J. S., Jr.; Silber, R.; Potmesil, M. Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin Cancer Res. 1991, 51, 3052-5
34. Pendrak, I.; Wittrock, R.; Kingsbury, W. D. Synthesis and Anti-Hsv Activity of Methylenedioxy Mappicine Ketone Analogs J. Org. Chem. 1995, 60, 2912-2915
35. Mahindroo, N.; Ahmed, Z.; Bhagat, A.; Bedi, K. L.; Khajuria, R. K.; Kapoor, V. K.; Mara, K. L. Synthesis and structure-activity relationships of vasicine analogues as bronchodilatory agents Med. Chem. Res. 2005, 14, 347-368 (Pubitemid 46170274)
36. Wall, M. E.; Wani, M. C.; Nicholas, A. W.; Manikumar, G.; Tele, C.; Moore, L.; Truesdale, A.; Leitner, P.; Besterman, J. M. Plant antitumor agents. 30. Synthesis and structure activity of novel camptothecin analogs J. Med. Chem. 1993, 36, 2689-700 (Pubitemid 23294136)
37. Bao, Y.; Zhang, L.; Chen, F. Synthesis of 5′(S)-1,1-dioxolane-5- oxo-(5′-ethyl-5′-hydroxyl-2′H,5′H,6′H-6-oxopyrano) -[3′,4′-f]-Δ(superscript 6(8))-tetrahydroindolizine Chin. J. Med. Chem. 2008, 4, 263-267
38. Bristol, J. A.; Comins, D. L.; Davenport, R. W.; Kane, M. J.; Lyle, R. E.; Maloney, J. R.; Portlock, D. E.; Horwitz, S. B. Analogs of camptothecin J. Med. Chem. 1975, 18, 535-537
39. Horwitz, M. S.; Horwitz, S. B. Intracellular degradation of HeLa and adenovirus type 2 DNA induced by camptothecin Biochem. Biophys. Res. Commun. 1971, 45, 723-7
40. Wu, R. S.; Kumar, A.; Warner, J. R. Ribosome Formation Is Blocked by Camptothecin, a Reversible Inhibitor of Rna Synthesis Proc. Natl. Acad. Sci. U.S.A. 1971, 68, 3009
41. Horwitz, S. B.; Chang, C. K.; Grollman, A. P. Studies on camptothecin. I. Effects of nucleic acid and protein synthesis Mol. Pharmacol. 1971, 7, 632-44
42. Hsiang, Y. H.; Hertzberg, R.; Hecht, S.; Liu, L. F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I J. Biol. Chem. 1985, 260, 14873-8 (Pubitemid 16211028)
43. Stewart, A. F.; Schutz, G. Camptothecin-induced in vivo topoisomerase I cleavages in the transcriptionally active tyrosine aminotransferase gene Cell 1987, 50, 1109-17
44. Andoh, T.; Ishii, K.; Suzuki, Y.; Ikegami, Y.; Kusunoki, Y.; Takemoto, Y.; Okada, K. Characterization of a mammalian mutant with a camptothecin- resistant DNA topoisomerase I Proc. Natl. Acad. Sci. U.S.A. 1987, 84, 5565-9
45. Barth, S. W.; Briviba, K.; Watzl, B.; Jager, N.; Marko, D.; Esselen, M. In vivo bioassay to detect irinotecan-stabilized DNA/topoisomerase I complexes in rats Biotechnol. J. 2010, 5, 321-7
46. Richter, S. N.; Nadai, M.; Palumbo, M.; Palu, G. Topoisomerase I involvement in schedule-dependent interaction between 5-fluoro-uracil and irinotecan in the treatment of colorectal cancer Cancer Chemother. Pharmacol. 2009, 64, 199-200
47. Horisberger, K.; Erben, P.; Muessle, B.; Woernle, C.; Stroebel, P.; Kaehler, G.; Wenz, F.; Hochhaus, A.; Post, S.; Willeke, F.; Hofheinz, R. D. Margit. Topoisomerase I expression correlates to response to neoadjuvant irinotecan-based chemoradiation in rectal cancer Anticancer Drugs 2009, 20, 519-24
48. Mathijssen, R. H.; Loos, W. J.; Verweij, J.; Sparreboom, A. Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan Curr. Cancer Drug Targets 2002, 2, 103-23 (Pubitemid 34625479)
49. Kostopoulos, I.; Karavasilis, V.; Karina, M.; Bobos, M.; Xiros, N.; Pentheroudakis, G.; Kafiri, G.; Papakostas, P.; Vrettou, E.; Fountzilas, G. Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy BMC Cancer 2009, 9, 339
50. DiSaia, P.; Sinkovics, J.; Rutledge, F.; Smith, J. Cell-mediated immunity to human malignant cells. A brief review and further studies with two gynecologic tumors Am. J. Obstet. Gynecol. 1972, 114, 979-989
51. Wadkins, R. M.; Potter, P. M.; Vladu, B.; Marty, J.; Mangold, G.; Weitman, S.; Manikumar, G.; Wani, M. C.; Wall, M. E.; Von Hoff, D. D. Water soluble 20(S)-glycinate esters of 10,11-methylenedioxycamptothecins are highly active against human breast cancer xenografts Cancer Res. 1999, 59, 3424-8 (Pubitemid 29334503)
52. Lerchen, H. G.; Baumgarten, J.; von dem Bruch, K.; Lehmann, T. E.; Sperzel, M.; Kempka, G.; Fiebig, H. H. Design and optimization of 20-O-linked camptothecin glycoconjugates as anticancer agents J. Med. Chem. 2001, 44, 4186-95 (Pubitemid 33095325)
53. Rose, W. C.; Marathe, P. H.; Jang, G. R.; Monticello, T. M.; Balasubramanian, B. N.; Long, B.; Fairchild, C. R.; Wall, M. E.; Wani, M. C. Novel fluoro-substituted camptothecins: in vivo antitumor activity, reduced gastrointestinal toxicity and pharmacokinetic characterization Cancer Chemother. Pharmacol. 2006, 58, 73-85
54. Cao, Z.; Harris, N.; Kozielski, A.; Vardeman, D.; Stehlin, J. S.; Giovanella, B. Alkyl esters of camptothecin and 9-nitrocamptothecin: synthesis, in vitro pharmacokinetics, toxicity, and antitumor activity J. Med. Chem. 1998, 41, 31-7 (Pubitemid 28070464)
55. Ling, X.; Bernacki, R. J.; Brattain, M. G.; Li, F. Induction of survivin expression by taxol (paclitaxel) is an early event, which is independent of taxol-mediated G2/M arrest J. Biol. Chem. 2004, 279, 15196-203 (Pubitemid 38618915)
56. Ling, X.; Yang, J.; Tan, D.; Ramnath, N.; Younis, T.; Bundy, B. N.; Slocum, H. K.; Yang, L.; Zhou, M.; Li, F. Differential expression of survivin-2B and survivin-DeltaEx3 is inversely associated with disease relapse and patient survival in non-small-cell lung cancer (NSCLC) Lung Cancer 2005, 49, 353-361 (Pubitemid 41139148)
57. Wu, J.; Ling, X.; Pan, D.; Apontes, P.; Song, L.; Liang, P.; Altieri, D. C.; Beerman, T.; Li, F. Molecular mechanism of inhibition of survivin transcription by the GC-rich sequence selective DNA-binding antitumor agent, hedamycin: evidence of survivin downregulation associated with drug sensitivity J. Biol. Chem. 2005, 280, 9745-51 (Pubitemid 40409673)
58. Cheng, Q.; Ling, X.; Haller, A.; Nakahara, T.; Yamanaka, K.; Kita, A.; Koutoku, H.; Takeuchi, M.; Brattain, M. G.; Li, F. Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter Int. J. Biochem. Mol. Biol. 2012, 3, 179-97